Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile

被引:21
|
作者
Odenholt, Inga [1 ]
Walder, Mats
Wullt, Marlene
机构
[1] Lund Univ, Dept Clin Sci, Infect Dis Res Unit, SE-20502 Malmo, Sweden
[2] Lund Univ, Dept Expt Sci, Malmo, Sweden
关键词
pharmacodynamic effect; postantibiotic effect; postantibiotic sub-MIC effect; Clostridium difficile; vancomycin; metronidazole; fusidic acid; STAPHYLOCOCCUS-AUREUS; DIARRHEA; SUSCEPTIBILITY; INFECTION; COLITIS; INVIVO; CIPROFLOXACIN; ROXITHROMYCIN; OUTBREAK; INVITRO;
D O I
10.1159/000104471
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pharmacodynamic studies of antibiotics have attracted great interest in recent years. However, studies on the pharmacodynamics of different antibiotics against Clostridium difficile are scarce. Methods: The postantibiotic effects (PAE) and the postantibiotic sub-minimum inhibitory concentration (MIC) effects (PA SME) of vancomycin, metronidazole and fusidic acid were investigated by viable counts against three different strains of C. difficile. The killing rate and extent of the three antibiotics against the same strains were also studied by adding 2, 4, 8, 16 and 32 ! MIC of the three antibiotics, respectively. Results: Metronidazole exerted a very rapid bactericidal effect at concentrations of 8 ! MIC and above against all three strains investigated. Vancomycin gave overall less kill in comparison to metronidazole and was bacteriostatic against two of the three strains. Fusidic acid exerted a concentration-dependent killing against two of the strains. Vancomycin exerted short PAEs and PA SMEs against all three strains. Significantly longer PAEs and PA SMEs were noted for fusidic acid. Metronidazole gave similar short PAEs like vancomycin but longer PA SMEs were noted against two of the investigated strains. Conclusion: Metronidazole exerted the most prominent bactericidal effect greater than fusidic acid and greater than vancomycin. Fusidic acid gave overall the longest PAEs and PA SMEs greater than metronidazole and greater than vancomycin. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 50 条
  • [41] Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy
    Tieu, Jennifer D.
    Schmidt, Sarah A.
    Miller, Jamie L.
    Kupiec, Katherine E.
    Skrepnek, Grant H.
    Liu, Connie
    Smith, Winter J.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 520 - 528
  • [42] PROSPECTIVE RANDOMIZED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHEA AND COLITIS
    TEASLEY, DG
    GERDING, DN
    OLSON, MM
    PETERSON, LR
    GEBHARD, RL
    SCHWARTZ, MJ
    LEE, JT
    LANCET, 1983, 2 (8358): : 1043 - 1046
  • [43] Reduced susceptibility of Clostridium difficile to metronidazole
    Brazier, JS
    Fawley, W
    Freeman, J
    Wilcox, MH
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) : 741 - 742
  • [44] A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity
    Di, Xiuzhen
    Bai, Nan
    Zhang, Xin
    Liu, Bin
    Ni, Wentao
    Wang, Jin
    Wang, Kai
    Liang, Beibei
    Liu, Youning
    Wang, Rui
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2015, 19 (04): : 339 - 349
  • [45] COST-EFFECTIVENESS OF FIDAXOMICIN VERSUS VANCOMYCIN AND METRONIDAZOLE IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION IN SPAIN
    Watt, M.
    de Nigris, E.
    McCrea, C.
    VALUE IN HEALTH, 2017, 20 (09) : A784 - A784
  • [46] ORAL METRONIDAZOLE IN CLOSTRIDIUM DIFFICILE COLITIS
    MOGG, GAG
    BURDON, DW
    KEIGHLEY, M
    BRITISH MEDICAL JOURNAL, 1979, 2 (6185): : 335 - 335
  • [47] Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
    Dubberke, Erik R.
    Gerding, Dale N.
    Kelly, Ciaran P.
    Garey, Kevin W.
    Rahav, Galia
    Mosley, Audrey
    Tipping, Robert
    Dorr, Mary Beth
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (06):
  • [48] Therapeutic success of rifaximin in the setting of Clostridium difficile diarrhea refractory to metronidazole and vancomycin: Case report
    Tannous, George C.
    Neff, Guy
    O'Toole, Terry
    Schmulewitz, Nathan
    Duncan, Christopher
    Zacharias, Victoria
    Kemmer, Nvingi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S401 - S401
  • [49] Clostridium difficile Recurrence in Abdominal Organ Transplant Recipients: Metronidazole versus Oral Vancomycin.
    Moorman, A.
    Todd, S.
    Lyon, G., III
    Triemer, H.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 883 - 883
  • [50] FUSIDIC ACID FOR THE TREATMENT OF ANTIBIOTIC-ASSOCIATED COLITIS INDUCED BY CLOSTRIDIUM-DIFFICILE
    CRONBERG, S
    CASTOR, B
    THOREN, A
    INFECTION, 1984, 12 (04) : 276 - 279